RINVOQ ® Now Available for Pediatric Patients with Arthritis

Tuesday, 4 June 2024, 09:48

The latest update announces the availability of RINVOQ ® (upadacitinib) for pediatric patients aged two and above with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis. This development brings a new treatment option for young patients suffering from these conditions, potentially improving their quality of life and overall well-being.

https://store.livarava.com/8846521f-2271-11ef-a3ff-9d5fa15a64d8.jpg — RINVOQ ® Now Available for Pediatric Patients with Arthritis

RINVOQ ® Pediatric Use for Arthritis Now Available

The recent announcement highlights a significant milestone in pediatric arthritis treatment with RINVOQ ® now approved for patients as young as two years old. This advancement provides new hope and options for children with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.